StockChartsAI.com
All Chart Prices Delayed at least 15 minutesBefore accessing this site, you agree that you have read and agree to the disclaimers at the bottom of this page.
Stock Charts AI Power Rank: 9.3
Power Rank trend -> Rising
10/08/2024 11:14:00 EST
Bristol-Myers Squibb Company (BMY)
Industry: Drug Manufacturers - General
Follow @stockchartsai on TwitterPrice Support Resistance
In the past 20 trading days, BMY has been trading in a range between $53.16 and $47.71 (gray range band). Red lines on the chart represent key resistance levels and Green lines represent key support levels. As the price moves above the lines you will notice they turn green and red if price moves below a line.
BMY is trading below resistance at $54.40, about 3% to the upside. There is support at $50.51 -5% to the downside. If it can break above the resistance, it could have some more upside. If the price starts to turn down and fails to get through this level or enters a yellow zone, we would consider profit taking or exiting the position. If it enters a red zone on the chart we would exit the position.
Upside / Downside Potential
Bristol-Myers Squibb Company $BMY entered a Green zone 15 days ago on the AI powered stock chart. Wall Street analysts have an AVG target price $71.57, a potential upside of 33.93% from the recent price of 53.44. The stock is trading 2.69% (potential upside) below its 52 week high of $54.88 and 38.45 % (potential downside) above its 52 week low of $38.60 - based on the recent price.
Company Summary
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.
News
| Buying Opportunities In Biotech And Pharma With Bhavneesh Sharma Kirk Spano and Bhavneesh Sharma talk biotech, pharma, and contrarian buying opportunities. AI is revolutionizing drug discovery by significantly speeding up the process and increasing the probability of successful outcomes, making it a game-changer for the biotech sector. Source: Seeking Alpha Sun, 06 Oct 2024 14:00:00 -0400 Sentiment: Positive |
| Bristol Myers Squibb: A High-Yield Bargain With Growth On The Horizon Frequent trading can erode gains due to transaction costs and taxes; a buy-and-hold strategy is often more effective for retail investors. Bristol Myers Squibb offers a strong dividend yield, below-average valuation, and solid growth prospects, making it a compelling buy. BMY's robust pipeline, including advancements in neurodegenerative therapies, and strong balance sheet support future growth and income potential. Source: Seeking Alpha Sun, 06 Oct 2024 10:30:00 -0400 Sentiment: Positive |
| Bristol Myers Squibb (BMY) Advances While Market Declines: Some Information for Investors The latest trading day saw Bristol Myers Squibb (BMY) settling at $54.20, representing a +0.82% change from its previous close. Source: Zacks Investment Research Thu, 03 Oct 2024 18:51:16 -0400 Sentiment: Neutral |
| U.S. Food and Drug Administration Approves Perioperative Treatment of Neoadjuvant Opdivo® (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Single-Agent Opdivo for Resectable Non-Small Cell Lung Cancer (NSCLC) PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CheckMate--U.S. FDA Approves Perioperative Treatment of Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Single-Agent Opdivo. Source: Business Wire Thu, 03 Oct 2024 17:35:00 -0400 Sentiment: Neutral |
| 2 Passive-Income Stocks to Load Up On in October These two dividend powerhouses are ideal choices for passive-income investors. Source: The Motley Fool Thu, 03 Oct 2024 06:45:00 -0400 Sentiment: Positive |
Technicals 52 Week Hi: 54.8753 52 Week Low: 38.6043 Beta: 0.46 50 Day MA: 49.347 200 Day MA: 47.7766 Earnings / Revenue Trends Qtr Earnings Growth YOY: -0.163 Qtr Revenue Growth YOY: 0.087 Forward PE: 7.6982 Trailing PE: 0